Iproteos-Sl-logo

Iproteos Sl

Biotechnology company based in Barcelona.
R&D therapeutic strategies of CNS diseases based on the modulation of protein-protein interactions. Iproteos S.L. is a biotechnology R&D company based on PPI modulation and protease inhibition for the treatment of diseases of the central nervous system (CNS).

Iproteos is Spin-off from the University of Barcelona & Institute for Research in Biomedicine of Barcelona, and is located at Barcelona Science Park, modulating protein-ligand (PLI) and protein-protein interactions (PPIs) through peptidomimetics.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.iproteos.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Baldiri Reixac, 10 Science Park,8028
Barcelona
Spain
Email
Contact Number
+34 93 402 09 06

Key partners includes Institute for Reseasrch in Biomedicine (Barcelona), Pharmaphenix, Centre for Genomic Regulation, Cibersam, ASCIL Biopharma and NeuroBio.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/iproteos” connections=”true” suffix=””]

Iproteos has developed a proprietary technology, named IPRO Technology, for the discovery and development of new pharmacological peptidomimetics for the modulation and disruption of either protein-protein or protein-ligand complexes involved in disease progression.

Jan 2017, Iproteos recevied grant of 700,000 ‹ for the discovery of drugs against atherosclerosis from The Spanish Ministry of Economy, Industry and Competitiveness.

Oct 2016, Iproteos closes a round of funding valued at 1.5 M ‹, led by Caixa Capital Risc and Kinled Holding and Ascil Biopharm for preclinical drug development of Cognitive Impairment Associated with Schizophrenia.